The arrival of amivantamab offers a exciting development click here for individuals battling cancers featuring c-MET overexpression. This innovative antibody, a targeted agent of both MET kinase plus human epidermal growth factor receptor 2 (HER2), demonstrated preliminary effectiveness in research studies, particularly in individuals whose tumors